February 18, 2022 Christopher Holt
This week, as states and municipalities moved to
lift COVID-19 restrictions and the rate of new infections plummeted, the Biden
Administration pressed lawmakers for another round of pandemic funding. Specifically, Department of Health and
Human Services (HHS) Secretary Xavier Becerra told Congress on Tuesday that HHS
needs another $30 billion immediately to continue its COVID-19 response. HHS’s
$30 billion request is likely just the tip of the iceberg; clearly, lawmakers
and the administration need a better process for funding pandemic response
going forward.
The HHS request is
limited to vaccines, diagnostics, and therapies, and may not be sufficient to
hold HHS over until the end of the fiscal year; further requests should be
expected this summer. Specifically, HHS wants $17.9 billion to
purchase oral antivirals, monoclonal antibodies, pediatric vaccines for
children ages 5-15, and for a slush fund to potentially purchase multivariant
vaccines should they be developed. An additional $4.9 billion would be used to
preserve manufacturing capacity of COVID-19 tests and testing supplies when
current demand diminishes, further expand the Increasing Community Access to
Testing program that provides no-cost testing to underserved communities,
continue the accelerated pathway for COVID-19 tests emergency use approval,
monitoring and evaluation of existing diagnostics effectiveness at identifying
new variants, and fund advanced purchases of diagnostics from manufacturers who
are close to receiving emergency approval but don’t have the funds to scale up
manufacturing capacity in advance. Then there is $3 billion to reimburse
providers for the testing, treatment, and vaccination of uninsured individuals,
$3.7 billion for the National Institutes of Health and the Biomedical Advanced
Research and Development Authority to support development of new vaccines that
would maintain their effectiveness against future variants, and last, $500 million
for ongoing surveillance aimed at detecting future variants.
Additional COVID-19-related funding requests are
likely, and in fact on Thursday there were reports that
the United States Agency for International Development may ask for as much as
$19 billion through September to fund U.S. efforts to distribute vaccines
internationally. In the meantime, Congress is working to finalize an
agreement to fund the entire federal government through September—the end of
the 2022 fiscal year. It is expected that the administration will attempt to
roll these and other COVID-19 funding requests into that process, which
lawmakers now hope to wrap up by March 11, just a few weeks short of halfway
through the fiscal year.
Stepping back to the larger picture, HHS is wise
to continue planning for future developments, and to seek to keep testing,
vaccination, and treatment capacity in place for any future variants. But at
the same time, Congress has appropriated roughly $4.6 trillion for
COVID-19 response through the end of 2021, but exactly how much of it has been
spent and on what isn’t entirely clear. As a prerequisite for any
additional emergency funding through the end of the fiscal year, lawmakers
would be justified in insisting on a full accounting from the administration as
to how previously appropriated dollars have or have not been spent, and what
monies might be available to be reallocated. Additionally, the
president’s budget, by law, is supposed to be submitted to Congress by the
first Monday in February. That date has obviously passed and there is no word
on when President Biden might submit his budget request, but when he does, it
should include all COVID-19-related spending for fiscal year 2023.
Pandemic funding going forward shouldn’t be done
on an ad hoc, emergency basis. We’ve been at this for two years—we should at
least be able to estimate what things will cost going forward and pay for it
through the regular budget and appropriations processes.
https://www.americanactionforum.org/weekly-checkup/putting-covid-19-in-the-budget/#ixzz7LmOxp600
Follow @AAF on Twitter
No comments:
Post a Comment